Tentarix Biotherapeutics Announces Three Collaborations, Plus Acquisition Options With Gilead Sciences

San Diego – August 15, 2023 – Cooley advised Tentarix Biotherapeutics and three of its subsidiaries on three multiyear collaborations with Gilead Sciences. Charity Williams and Rama Padmanabhan led the Cooley team advising Tentarix, which also included Lindsey O’Crump, Ritu Gupta, Jameson Davis and Joshua Allen.

The collaboration combines Tentarix’s proprietary Tentacles platform with Gilead’s oncology and inflammation know-how to discover and develop multifunctional, conditional protein therapeutics for oncology and inflammatory diseases. Tentarix will receive upfront payments and an equity investment from Gilead totaling $66 million, with an option for Gilead to acquire the three Tentarix’s subsidiaries containing the programs developed under the collaborations for $80 million per subsidiary.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.